
**Please do not contact me via DM with clinical or professional queries - contact my PA at sarcoma.medsecchelsea@rmh.nhs.uk**

All personally tweeted views are my own.

**Please do not contact me via DM with clinical or professional queries - contact my PA at sarcoma.medsecchelsea@rmh.nhs.uk**

Excited to be here at #CTOS2026 ! Looking forward to learning about the latest advances and updates in sarcoma, connecting with clinicians and researchers from around the 🌎, and building connections with patient advocacy orgs. 💛 #CTOS2026 #Sarcoma #gist #Liposarcoma #TGCT

@ctosociety #Ctos2026 Amazing to see how much @TARPSWG has grown over the years - love the collaboration, drive and innovation to change the landscape for patients with #Retroperitoneal #Sarcoma #Seoul @SocSurgOnc


Nov 14. Working on my speech for WHO Executive Board's meeting with the candidates. Thank you so much for all the birthday wishes, my dear friends. Your every word means a lot to me ☺️

Today, I am sharing “Geography Must Not Decide Who Lives” — my program as a candidate for World Health Organization Director-General. linkedin.com/posts/gevorgtam… It reflects months of work. I have asked for advice, listened to people from around the world, read my fellow candidates’ programs and learned from their ideas too. I have included proposals that reflect my vision and make it stronger. A good idea does not need my name on it. But this is a living document. It is not written in stone. And today, I am inviting you to help improve it. Give Me Five 🖐 5 suggestions on what @WHO should do, or stop doing. Something that needs to change immediately, in the next few years, or over the longer term. You do not need to be a global health expert to have something important to say. I want to hear from health workers, patients, families, researchers, and anyone who believes WHO can serve people better. From every part of the world. Please send your suggestions through our wonderful team members, Dr. Jemma Arakelyan (jemma.arakelyan@oncodaily.com)and Dr. Arpi Asminian (arpi.asminian@oncodaily.com). I promise to read every submission. By the end of this year, we will bring the suggestions together and publish them. Thank you for your time, your trust and your support. I believe we can create lasting change together, for a healthier and better world 🤝🌐 The World Must Have WHO. WHO for U. #WHO4U #WHO4You #GiveMe5

⭐️New city, new chapter, same mission 🗽 ⭐️Thrilled to have joined @nyulangone @Perlmutter_CC to lead Early Phase Drug Development and the Rare Cancer Programs. ⭐️For patients with rare cancers, #PrecisionMedicine should open the door to treatment. Expanding access to early-phase trials is how we make that real. ⭐️My work has always been tumor-agnostic. That continues here, now geography agnostic & zip code agnostic too. ⭐️Such a delight to be in NY with family. Grateful to @Aiims1742, @JohnPLeonardMD & @nyuniversity @nyulangone visionary leadership for bringing me here! ⭐️Thank you to all my friends & colleagues for the wishes & the outpouring of support🙏 @OncoAlert @oncodaily @ASCO @ASCOPost tinyurl.com/238ks5m5
🏥 @nyulangone Perlmutter Cancer Center has appointed @VivekSubbiah, MD, Director of Early-Phase Drug Development and Rare Cancer Programs. 🩺 He brings 15+ years of experience in #PrecisionOncology and clinical research. Learn more ➡️ ascopost.com/news/november-2…

National Cancer Policy Summit: Progress in Policy and Science and the Future of Cancer Research and Care - Monica Bertagnolli @theNAMedicine &Tony Letai @NCIDirector @theNCI, and our stellar panel on 20 years of cancer care - lessons learned and new opportunities. @ASCO

Very pleased to see an #NSCLC medicine selected for the current round of @MHRAgovuk #ILAP passports (BGB-58067, a PRMT5i @BeOneMedicines) This whole system approach to development and reimbursement submission is the type of coordinated approach UK needs.
Three medicines in development for lung cancer, Huntington's disease and Alzheimer's disease have been awarded MHRA Innovation Passports. The designation gives developers access to the UK's Innovative Licensing and Access Pathway (ILAP), but it does not mean the medicines are approved or available on the NHS. Applications for the next round close on 11 February 2027. Read more: ukpoliticsdecoded.uk/decoded…


Fred Hutch and the University of Washington are seeking an leader to serve as Program Head of Gastrointestinal Oncology. This role will guide a program spanning clinical care, translational science, clinical trials, mentorship and strategic growth. Apply: apply.interfolio.com/187233

WHO in every country. Every country that wants it. Recently, during a meeting with representatives of a country without its own @WHO country office, we discussed this. They made it clear: they would be happy to host one. And I think the principle should be simple. If a country wants WHO physically present, we should work together to make it happen. According to WHO's 2025 country presence report, 19 countries are served by five multi-country offices. But being served from another capital and having someone there, working with your ministry of health every day, are different things. Under my leadership, no Member State that asks for a WHO presence will be told no because it is too small. I will work with the Regional Directors and Member States to make this real. Whether a country has 10,000 people or 100 million does not matter. A small state is still a state. Its people still face outbreaks, shortages of medicines, a cancer diagnosis in a child. The question is whether WHO is close enough to be useful. This does not always require a separate building or a large team. It may begin with one WHO liaison officer working inside the ministry of health. The arrangement can be different. The commitment must be the same. Some countries may not need or want a country office. That is their decision. But for those that do, the door must be open. WHO was built by countries, for countries. It should live in them. Geography must not decide who lives✊️🌐

👉 Dr. Sandra D'Angelo, New York, USA, is looking for research that helps crack the code of immune resistance in sarcoma. Could your work be the next step forward for patients? Submit your abstract by 24 November. 🔗 ow.ly/guch5100oml #ESMORareCancers27 #esmomeetings

“Moving the Needle" #ASCyto26, the 74th Annual Scientific Meeting of the American Society of Cytopathology @cytopathology, starts today in the beautiful city of Seattle. #CytoPath

Fred Hutch Cancer Center scientists Roland Walter, MD, PhD, and Jennifer Lund, PhD, recently received prestigious R01 grants from the @NIH to support major projects with well-defined goals and compelling potential to benefit public health. Read more: bit.ly/4yXByCO

Thank you so much for your trust and support, my dear friends in Albania🙏😊 As you well said, together for every child 🤝✊️🌐 Geography must not decide who lives ✊️